Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Sentinel Likely To Outpace Traditional Post-Market Studies, But Will It Replace Them?

This article was originally published in The Pink Sheet Daily

Executive Summary

Pilot project for overactive bladder drug Mybretriq raises questions as to how Sentinel will affect sponsor’s risk-monitoring obligations.

You may also be interested in...



FDA Sentinel Transition Will Involve Expanding Rx Safety Data Sources

Moving Mini-Sentinel pilot program to a fully operational and sustainable Sentinel postmarket safety surveillance system will take place over next year, CDER Director Woodcock says.

Adverse Event Reports Rising Faster Than FDA Adds Surveillance Staff

Adverse event reports submitted each year have quadrupled over the last decade, and FDA expects the reports to retain their value in ensuring product safety even as more technology helps with drug safety monitoring.

Adverse Event Reports Rising Faster Than FDA Adds Surveillance Staff

Adverse event reports submitted each year have quadrupled over the last decade, and FDA expects the reports to retain their value in ensuring product safety even as more technology helps with drug safety monitoring.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel